Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy

Kathrin Tyryshkin, PhD, Yi D Li, MD, David Good, MD, Lois E. Shepherd, MD, Tara Baetz, MD FRCPC, Michael J. Rauh, MD PhD, David P. LeBrun, MD

Blood (2016) 128 (22): 3037.

https://doi.org/10.1182/blood.V128.22.3037.3037

Published: 2016

Journal Articles

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Tony Reiman, MD, Kerry J. Savage, MD MSc, Michael Crump, MD, Matthew Cheung, MD, David A. MacDonald, MD, Rena Buckstein, MD, Stephen Couban, MD, Eugenia Piliotis, MD, Kevin R Imrie, MD, David Spaner, MD PhD, Sudeep Shivakumar, MD, John Kuruvilla, MD, Diego Villa, Lois E. Shepherd, MD, Tanya Skamene, MD, Chad Winch, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 4162.

https://doi.org/10.1182/blood.V128.22.4162.4162

Published: 2016

Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Darrell J. White, MD, Michael J. Kovacs, MD, Andrew Belch, MD, Keith Stewart, MB, ChB, Christine Chen, MD, Sheldon Rubin, MD, David A. Macdonald, MD, Erica Harnett, MSc, Judy-Anne W. Chapman, PhD, Lois E. Shepherd, MD, Ralph M. Meyer, MD

Blood (2007) 110 (11): 189.

https://doi.org/10.1182/blood.V110.11.189.189

Published: 2007

Journal Articles

Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.

Cynthia Luk, MD, Keyue Ding, PhD, Andrew R. Belch, MD, George P. Browman, MD, Chaim Shustik, MD, Marina Djurfeldt, MSc, Dianne Johnston, Lois E. Shepherd, MD, Ralph M. Meyer, MD

Blood (2005) 106 (11): 2568.

https://doi.org/10.1182/blood.V106.11.2568.2568

Published: 2005

Journal Articles

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

David A. Macdonald, MD, Mary K. Gospodarowicz, MD, Woodrow A. Wells, MD, Robert G. Pearcey, MD, Joseph M. Connors, MD, Jane N. Winter, MD, Sandra J. Horning, MD, Marina S. Djurfeldt, MSc, Keyue Ding, PhD, Lois E. Shepherd, MD, Ralph M. Meyer, MD

Blood (2005) 106 (11): 817.

https://doi.org/10.1182/blood.V106.11.817.817

Published: 2005

NARROW

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

Email alerts

ASH Publications

American Society of Hematology

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Differential Expression of TCF3 Target Genes Defines Subclasses of Diffuse Large B-Cell Lymphoma with Striking Differences in Clinical Outcome Following R-CHOP Therapy

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only